Monitoring MRD in Patients with AML

Video

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease (MRD) in patients with acute myeloid leukemia (AML).

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
Addressing Financial Toxicity and Food Insecurity in Cancer Care

Addressing Financial Toxicity and Food Insecurity in Cancer Care

Sabrina Serani
July 16th 2025
Article

Read More

Dr Weiss Reviews Key Melanoma Updates From ASCO 2025

Dr Weiss Reviews Key Melanoma Updates From ASCO 2025

Jordyn Sava
July 15th 2025
Article

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant therapy and brain metastases management.

Read More

Immunotherapy Advances and Challenges in T-Cell Lymphoma

Immunotherapy Advances and Challenges in T-Cell Lymphoma

Jordyn Sava
July 14th 2025
Article

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new treatment options.

Read More

Why Telemedicine Is Now Essential in Oncology: Insights From Dr Phull

Why Telemedicine Is Now Essential in Oncology: Insights From Dr Phull

Jordyn Sava
July 14th 2025
Article

Hardeep Phull, MD, shared how telemedicine has transformed access, improved patient experience, and redefined care delivery for patients with cancer.

Read More

FDA Reviews All-Oral Decitabine/Cedazuridine/Venetoclax Combo in AML

FDA Reviews All-Oral Decitabine/Cedazuridine/Venetoclax Combo in AML

Jordyn Sava
July 11th 2025
Article

The FDA reviews an all-oral treatment for newly diagnosed AML, combining decitabine, cedazuridine, and venetoclax, showing promising trial results.

Read More

Fixed-Duration Ibrutinib/Venetoclax Shows Durable Responses in CLL, Says Dr Ghia

Fixed-Duration Ibrutinib/Venetoclax Shows Durable Responses in CLL, Says Dr Ghia

Jordyn Sava
July 11th 2025
Article

New findings reveal that fixed-duration ibrutinib plus venetoclax offers long-term efficacy and safety for patients with untreated chronic lymphocytic leukemia.

Read More